← Back to Search

Behavioural Intervention

rtACS Stimulation for Glaucoma

Waitlist Available
Led By Heather Livengood, PhD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights


This trial will test whether an electric current intervention can help treat visual impairment for people with glaucoma and improve their quality of life.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Humphrey Visual Field Analyzer Score
Change in Macular Ganglion Cell-Inner Plexiform Layer Thickness
Change in Minnesota Low Vision Reading Test (MNRead): Reading Acuity Score
+17 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: rtACS Stimulation GroupExperimental Treatment1 Intervention
Group II: Sham Intervention GroupPlacebo Group1 Intervention
Sham stimulation looks like rtACS, but is not active rtACS.
First Studied
Drug Approval Stage
How many patients have taken this drug
rtACS Stimulation

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,379 Previous Clinical Trials
848,100 Total Patients Enrolled
7 Trials studying Glaucoma
1,681 Patients Enrolled for Glaucoma
Heather Livengood, PhDPrincipal InvestigatorNYU Langone Health
Joel Schuman, MD, FACSPrincipal InvestigatorNYU Langone Health
~2 spots leftby Jul 2025